Clinically Proven Enhanced Absorption

Davos Life Science commissioned an opened-label, randomised, 4-way cross-over clinical study to compare the bioavailability of DavosLife E3 Bio-Enhanced 20 with a market sample. This study was conducted on 28 healthy volunteers with a dosage of 200 mg Tocotrienols. DavosLife E3 Bio-Enhanced 20 delivers a higher concentration of Tocotrienols (Cmax) to plasma compared to the market sample at the same time point.

The Area Under the Curve (AUC) of Figure 1 represents the overall exposure of the body to Tocotrienols over time. DavosLife E3 Bio-Enhanced 20 has the greater AUC compared to the market sample and therefore the higher bioavailability between the two.

More Individual Isomers Delivered to Plasma

Higher concentrations of each individual Tocotrienols isomer in DavosLife E3 Bio-Enhanced 20 is delivered to plasma compared to the market sample.